2 citations,
August 2016 in “Experimental Dermatology” Finasteride treats baldness but may cause lasting sexual side effects.
2 citations,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
1 citations,
March 2023 in “Scientific Reports” Finasteride may increase the risk of suicide or severe self-harm in men with mood disorders but not in the general population.
1 citations,
August 2022 in “Veterinary medicine and science” The main prostate diseases in dogs are benign growth, infections, and cancer, with various treatments ranging from drugs to surgery, but cancer treatments have limited success.
1 citations,
November 2021 in “British Journal of Clinical Pharmacology” Saw palmetto may cause erectile dysfunction and needs better safety monitoring.
1 citations,
October 2020 in “The Egyptian Journal of Histology” Ginseng was more effective than finasteride in treating enlarged prostate in rats.
1 citations,
December 2018 in “Journal of Cosmetic Dermatology” Men with thinner hair from genetic hair loss may be more likely to have an enlarged prostate.
1 citations,
July 2018 in “Current Sexual Health Reports” Post-finasteride Syndrome causes lasting negative effects, but more research is needed for treatment and risk evaluation.
1 citations,
August 2015 in “Current Sexual Health Reports” 5α-reductase inhibitors can cause serious and possibly lasting sexual and psychological side effects.
1 citations,
December 2013 in “Urological Science” A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.
1 citations,
February 2008 in “Nature Clinical Practice Urology” Finasteride's sexual side effects may be due to nocebo effect.
September 2024 in “LUTS Lower Urinary Tract Symptoms” People with hair loss may have worse urinary symptoms due to an enlarged prostate.
August 2024 in “Australasian Journal of Dermatology” Finasteride users have a very low risk of mental health issues, but those with hair loss may have slightly higher anxiety and depression.
Higher doses of 5α-reductase inhibitors reduce mortality risk, while lower doses increase suicide risk.
May 2024 in “KIU journal of health science” Kolaviron and quercetin may help treat prostate issues.
April 2024 in “The Journal of urology/The journal of urology” SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.
April 2024 in “International journal of impotence research” Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.
October 2023 in “Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy” New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.
August 2023 in “Malaysian Journal of Medicine and Health Sciences/Malaysian journal of medicine and health sciences” Pueraria mirifica extract may help treat benign prostatic hyperplasia.
June 2023 in “Research Square (Research Square)” A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.
April 2023 in “Jordan Medical Journal” Men with male pattern baldness are more likely to have benign prostatic hyperplasia.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
Men with benign prostate hyperplasia have more meibomian gland loss and tear film problems.
March 2020 in “StatPearls” Medicines called 5-alpha-reductase inhibitors, like finasteride and dutasteride, are useful for treating enlarged prostate and male pattern hair loss.
Androgens increase norepinephrine release, promoting smooth muscle growth in male sex organs, which may contribute to benign prostatic hypertrophy.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
January 2018 in “Universidad Privada Antenor Orrego” Male pattern baldness may be an early sign of noncancerous prostate enlargement.
October 2017 in “The Journal of Urology” Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.